Leinco Technologies

Angiotensin-Converting Enzyme 2 (NT) Blocking Peptide

Product Code:
 
LEI-A297
Product Group:
 
Peptides
Regulatory Status:
 
RUO
Shipping:
 
Ambient
Storage:
 
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-A297-50ug50 ug£216.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
0.2 mg/ml
Format:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Formulation:
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Long Description:
Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin[1-9].1 ,or the conversion of angiotensin II to angiotensin 1-7.2 ACE 2 has direct effects on cardiac function2, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys.3 ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH).4 ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).5
Target:
Angiotensin-Converting Enzyme 2

References

1. Acton S et al. (2000) Circ Res. 87: E1 2. Gamliel-Lazarovich A et al. (2007) Cardiovasc Res. 73: 463 3. Nabel EG et al. (2000) N Engl J Med. 347: 1795 4. Raizada MK et al. (2009) Am J Respir Crit Care Med. 5. Yuan Y et al. (2009) Tohoku J Exp Med. 217: 123